Magnesiiumsulfaat Teva (Magnesium Sulfate)

Magnesium sulfate releases magnesium ions that act as cofactors for many enzymatic processes, stabilize neuronal membranes, and antagonise calcium entry. This reduces neuronal excitability, relaxes smooth muscle, lowers vascular tone, and helps normalise cardiac electrical activity, which together address the clinical conditions for which the drug is indicated.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function and therapeutic goal. Healthcare professionals follow local guidelines and adjust the regimen according to clinical response and laboratory monitoring.

Safety data in pregnancy are limited, but magnesium sulfate is commonly used when the benefit to the mother outweighs potential fetal risk, such as in eclampsia. It is excreted in breast milk in small amounts; breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Magnesium sulfate is the most widely used intravenous magnesium formulation because of its rapid bioavailability and well‑characterised safety profile. Alternatives such as magnesium chloride or magnesium gluconate are often oral or topical and have different pharmacokinetics, making magnesium sulfate the preferred choice for acute electrolyte correction and obstetric emergencies.

The product should be stored at temperatures below 25 °C, in its original sealed container, protected from moisture and direct sunlight. Before use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

Magnesiiumsulfaat Teva is supplied as a sterile solution for intravenous, intra‑articular or peri‑articular injection. Administration is performed by a qualified healthcare professional, following aseptic technique and appropriate infusion rates or injection volumes as dictated by the clinical indication.

Serious adverse events include severe hypotension, respiratory depression, cardiac arrest, anaphylaxis, hypermagnesemia leading to neuromuscular paralysis, and local tissue necrosis at the injection site. Prompt recognition and supportive measures are essential if any of these reactions occur.

Magnesium sulfate is contraindicated in patients with known hypersensitivity to magnesium salts, severe renal failure where clearance is markedly reduced, and in those with existing hypermagnesemia. Caution is also advised for individuals with myasthenia gravis or other neuromuscular disorders.